Notice: This company has been marked as potentially delisted and may not be actively trading. Vaccitech (VACC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesInsider TradesOwnershipTrends VACC vs. NVCT, IVA, MGNX, OGI, ACRS, ACTU, RENB, TSVT, SLN, and ZNTLShould you be buying Vaccitech stock or one of its competitors? The main competitors of Vaccitech include Nuvectis Pharma (NVCT), Inventiva (IVA), MacroGenics (MGNX), Organigram (OGI), Aclaris Therapeutics (ACRS), Actuate Therapeutics (ACTU), Renovaro (RENB), 2seventy bio (TSVT), Silence Therapeutics (SLN), and Zentalis Pharmaceuticals (ZNTL). These companies are all part of the "pharmaceutical preparations" industry. Vaccitech vs. Nuvectis Pharma Inventiva MacroGenics Organigram Aclaris Therapeutics Actuate Therapeutics Renovaro 2seventy bio Silence Therapeutics Zentalis Pharmaceuticals Nuvectis Pharma (NASDAQ:NVCT) and Vaccitech (NASDAQ:VACC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability. Do analysts rate NVCT or VACC? Nuvectis Pharma presently has a consensus target price of $11.00, suggesting a potential upside of 46.57%. Given Nuvectis Pharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe Nuvectis Pharma is more favorable than Vaccitech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvectis Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Vaccitech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders and institutionals believe in NVCT or VACC? 96.8% of Nuvectis Pharma shares are owned by institutional investors. Comparatively, 26.1% of Vaccitech shares are owned by institutional investors. 35.8% of Nuvectis Pharma shares are owned by insiders. Comparatively, 6.0% of Vaccitech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media prefer NVCT or VACC? In the previous week, Nuvectis Pharma had 2 more articles in the media than Vaccitech. MarketBeat recorded 2 mentions for Nuvectis Pharma and 0 mentions for Vaccitech. Vaccitech's average media sentiment score of 0.00 beat Nuvectis Pharma's score of -0.38 indicating that Vaccitech is being referred to more favorably in the news media. Company Overall Sentiment Nuvectis Pharma Neutral Vaccitech Neutral Does the MarketBeat Community prefer NVCT or VACC? Vaccitech received 7 more outperform votes than Nuvectis Pharma when rated by MarketBeat users. However, 90.91% of users gave Nuvectis Pharma an outperform vote while only 70.83% of users gave Vaccitech an outperform vote. CompanyUnderperformOutperformNuvectis PharmaOutperform Votes1090.91% Underperform Votes19.09%VaccitechOutperform Votes1770.83% Underperform Votes729.17% Which has more risk and volatility, NVCT or VACC? Nuvectis Pharma has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500. Comparatively, Vaccitech has a beta of -0.4, suggesting that its share price is 140% less volatile than the S&P 500. Which has stronger valuation & earnings, NVCT or VACC? Vaccitech has higher revenue and earnings than Nuvectis Pharma. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Vaccitech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvectis PharmaN/AN/A-$22.26M-$1.11-6.76Vaccitech$13.42M2.76$5.34M-$1.43-0.67 Is NVCT or VACC more profitable? Nuvectis Pharma has a net margin of 0.00% compared to Vaccitech's net margin of -409.18%. Vaccitech's return on equity of -23.41% beat Nuvectis Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Nuvectis PharmaN/A -155.80% -104.02% Vaccitech -409.18%-23.41%-20.85% SummaryNuvectis Pharma beats Vaccitech on 10 of the 17 factors compared between the two stocks. Remove Ads Get Vaccitech News Delivered to You Automatically Sign up to receive the latest news and ratings for VACC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VACC vs. The Competition Export to ExcelMetricVaccitechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$37.01M$6.93B$5.63B$8.06BDividend YieldN/A2.71%4.89%4.04%P/E Ratio-0.676.1423.7918.96Price / Sales2.76223.75381.68117.09Price / Cash19.3065.6738.0534.62Price / Book0.156.586.874.23Net Income$5.34M$139.77M$3.19B$246.59M Vaccitech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VACCVaccitechN/A$0.96flatN/A-63.1%$37.01M$13.42M-0.6733Gap UpNVCTNuvectis Pharma2.5772 of 5 stars$6.34+3.3%$11.00+73.5%-27.8%$148.31MN/A-5.478Short Interest ↓IVAInventiva2.2718 of 5 stars$2.82-4.7%$12.60+346.8%-22.9%$147.99M$15.62M0.00100Gap UpHigh Trading VolumeMGNXMacroGenics3.785 of 5 stars$2.32+1.8%$7.63+228.7%-86.5%$145.61M$139.77M-1.47430OGIOrganigram0.5153 of 5 stars$1.10+2.8%N/A-49.3%$138.84M$166.12M-2.89860Positive NewsGap UpACRSAclaris Therapeutics2.561 of 5 stars$1.93-1.5%$11.00+469.9%+27.9%$137.86M$27.08M-3.71100ACTUActuate TherapeuticsN/A$7.02+7.8%N/AN/A$137.12MN/A0.0010RENBRenovaro0.8914 of 5 stars$0.85-5.2%N/A-70.8%$134.42MN/A-0.9120TSVT2seventy bio3.1352 of 5 stars$2.60+4.8%$7.20+176.9%+8.1%$134.13M$45.62M-1.40440Analyst ForecastNews CoverageSLNSilence Therapeutics2.3454 of 5 stars$4.48+3.7%$41.33+822.6%-82.6%$134.09M$16.25M-2.85100ZNTLZentalis Pharmaceuticals2.0708 of 5 stars$1.87-2.6%$8.24+340.9%-86.8%$133.27M$40.56M-0.75160Positive NewsGap Up Remove Ads Related Companies and Tools Related Companies Nuvectis Pharma Competitors Inventiva Competitors MacroGenics Competitors Organigram Competitors Aclaris Therapeutics Competitors Actuate Therapeutics Competitors Renovaro Competitors 2seventy bio Competitors Silence Therapeutics Competitors Zentalis Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VACC) was last updated on 3/12/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump announces revenge on BidenA former CIA insider just made a stunning prediction: Trump’s revenge on Biden will end America’s energy cr...Paradigm Press | SponsoredMagnificent 7 wipeout: What's next?A massive wave of volatility is sweeping the stock market... After the recent selloff, the "Magnificent Sev...Chaikin Analytics | SponsoredWarren Buffet Just Made a $334 Billion BetDebt is out of control. Inflation is creeping back. And a major market downturn could be right around the corn...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaccitech plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaccitech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
